Print this page

Ovarian Cancer

Ovarian Cancer Clinical Trials Now Enrolling:

GOG0212 - A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or OPAXIO™ (formerly known as XYOTAX) versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy.
Learn more about this trial and search for a location near you

What is OPAXIO™? OPAXIO (Oh-packs-ee-oh) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. Learn more about OPAXIO and other clinical research

Taxol® is a registered trademark of Bristol-Myers Squibb Co.